MX2022005494A - Sistemas de residencia gastrica para la administracion de agentes activos. - Google Patents
Sistemas de residencia gastrica para la administracion de agentes activos.Info
- Publication number
- MX2022005494A MX2022005494A MX2022005494A MX2022005494A MX2022005494A MX 2022005494 A MX2022005494 A MX 2022005494A MX 2022005494 A MX2022005494 A MX 2022005494A MX 2022005494 A MX2022005494 A MX 2022005494A MX 2022005494 A MX2022005494 A MX 2022005494A
- Authority
- MX
- Mexico
- Prior art keywords
- gastric residence
- disclosed
- administration
- gastric
- active agents
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0065—Forms with gastric retention, e.g. floating on gastric juice, adhering to gastric mucosa, expanding to prevent passage through the pylorus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Molecular Biology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Inorganic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (8)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962933210P | 2019-11-08 | 2019-11-08 | |
| US201962933226P | 2019-11-08 | 2019-11-08 | |
| US201962933313P | 2019-11-08 | 2019-11-08 | |
| US201962933348P | 2019-11-08 | 2019-11-08 | |
| US201962933211P | 2019-11-08 | 2019-11-08 | |
| US202062992075P | 2020-03-19 | 2020-03-19 | |
| US202063052905P | 2020-07-16 | 2020-07-16 | |
| PCT/US2020/059541 WO2021092491A1 (en) | 2019-11-08 | 2020-11-06 | Gastric residence systems for administration of active agents |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2022005494A true MX2022005494A (es) | 2022-08-11 |
Family
ID=75849597
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2022005494A MX2022005494A (es) | 2019-11-08 | 2020-11-06 | Sistemas de residencia gastrica para la administracion de agentes activos. |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20220387311A1 (https=) |
| EP (1) | EP4054545A4 (https=) |
| JP (1) | JP2022553862A (https=) |
| CN (1) | CN115003335A (https=) |
| AU (1) | AU2020378438A1 (https=) |
| BR (1) | BR112022008908A2 (https=) |
| CA (1) | CA3160665A1 (https=) |
| IL (1) | IL292849A (https=) |
| MX (1) | MX2022005494A (https=) |
| WO (1) | WO2021092491A1 (https=) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2020117855A1 (en) | 2018-12-03 | 2020-06-11 | Lyndra, Inc. | Stomach simulating device |
| MX2021011314A (es) | 2019-03-20 | 2021-12-10 | Lyndra Therapeutics Inc | Capsulas y recubrimientos de capsulas para formas de dosificacion de residencia gastrica. |
| JP2022525482A (ja) | 2019-03-20 | 2022-05-16 | リンドラ セラピューティクス， インコーポレイティド | 胃内滞留剤形用のコーティング |
| CN116234540A (zh) | 2020-07-29 | 2023-06-06 | 赛康特集团有限责任公司 | 具有包括交联聚(癸二酸甘油酯)的结构的形状引导控释和滞留 |
| AU2022210426A1 (en) * | 2021-01-19 | 2023-08-24 | Nortiva Bio, Inc. | Gastric residence systems for administration of risperidone |
| CA3248763A1 (en) * | 2022-01-19 | 2023-07-27 | Nortiva Bio, Inc. | Dosage forms for gastric retention |
| CN115227879B (zh) * | 2022-09-15 | 2023-01-06 | 北京天星博迈迪医疗器械有限公司 | 一种用于可降解关节球囊的组合物及其应用、一种可降解关节球囊及其制备方法 |
| WO2024249946A2 (en) * | 2023-06-02 | 2024-12-05 | Lyndra Therapeutics, Inc. | Manufacturing methods for gastric residence systems |
| WO2025042350A1 (en) * | 2023-08-24 | 2025-02-27 | Junion Therapeutics (Xiamen) Co., Ltd. | A gastric residence article for oral administration |
| WO2025042349A1 (en) * | 2023-08-24 | 2025-02-27 | Junion Therapeutics (Xiamen) Co., Ltd. | A gastric residence article for oral administration |
| WO2025148850A1 (zh) * | 2024-01-09 | 2025-07-17 | 厦门君德医药科技有限公司 | 一种胃滞留装置 |
| WO2025153071A1 (en) * | 2024-01-18 | 2025-07-24 | Junion Therapeutics (Xiamen) Co., Ltd. | Gastric residence article for oral administration |
| WO2025195482A1 (zh) * | 2024-03-22 | 2025-09-25 | 厦门君德医药科技有限公司 | 一种胃滞留装置 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9925962D0 (en) * | 1999-11-02 | 1999-12-29 | Novartis Ag | Organic compounds |
| MX2008009125A (es) * | 2006-01-18 | 2008-10-23 | Qps Llc | Composiciones farmaceuticas con estabilidad mejorada. |
| ES2368356T3 (es) * | 2007-07-06 | 2011-11-16 | Basf Corporation | Composición de retención gástrica basada en un producto de reacción hidrosoluble procedente de un precursor que contiene un grupo vinilo. |
| JP5905872B2 (ja) * | 2010-04-07 | 2016-04-20 | ルピン・リミテッド | タペンタドールの制御放出医薬組成物 |
| JP5954669B2 (ja) * | 2010-08-06 | 2016-07-20 | エンドゥーシェイプ インコーポレイテッド | 医療デバイス用放射線不透過性形状記憶ポリマー |
| WO2015191922A1 (en) * | 2014-06-11 | 2015-12-17 | Massachusetts Institute Of Technology | Enteric elastomers |
| HK1258050A1 (zh) * | 2015-10-23 | 2019-11-01 | Lyndra Therapeutics, Inc. | 用於治疗剂缓释的胃驻留系统及其使用方法 |
| EP3386488B1 (en) * | 2015-12-08 | 2023-09-06 | Lyndra Therapeutics, Inc. | Geometric configurations for gastric residence systems |
| AU2017268840B2 (en) * | 2016-05-27 | 2022-02-10 | Nortiva Bio, Inc. | Materials architecture for gastric residence systems |
| US11576866B2 (en) * | 2016-09-30 | 2023-02-14 | Lyndra Therapeutics, Inc. | Gastric residence systems for sustained delivery of adamantane-class drugs |
| US12023406B2 (en) * | 2017-06-09 | 2024-07-02 | Lyndra Therapeutics, Inc. | Gastric residence systems with release rate-modulating films |
| AU2018337837B2 (en) * | 2017-09-20 | 2024-03-07 | Nortiva Bio, Inc. | Encapsulation of gastric residence systems |
| KR20220002905A (ko) * | 2019-03-25 | 2022-01-07 | 더글라스 파머수티클스 리미티드 | 서방형 약학 제제 |
-
2020
- 2020-11-06 US US17/774,132 patent/US20220387311A1/en active Pending
- 2020-11-06 BR BR112022008908A patent/BR112022008908A2/pt not_active Application Discontinuation
- 2020-11-06 JP JP2022526215A patent/JP2022553862A/ja active Pending
- 2020-11-06 EP EP20884024.9A patent/EP4054545A4/en active Pending
- 2020-11-06 CA CA3160665A patent/CA3160665A1/en active Pending
- 2020-11-06 CN CN202080092586.2A patent/CN115003335A/zh active Pending
- 2020-11-06 MX MX2022005494A patent/MX2022005494A/es unknown
- 2020-11-06 WO PCT/US2020/059541 patent/WO2021092491A1/en not_active Ceased
- 2020-11-06 AU AU2020378438A patent/AU2020378438A1/en active Pending
-
2022
- 2022-05-08 IL IL292849A patent/IL292849A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| IL292849A (en) | 2022-07-01 |
| US20220387311A1 (en) | 2022-12-08 |
| WO2021092491A1 (en) | 2021-05-14 |
| CA3160665A1 (en) | 2021-05-14 |
| JP2022553862A (ja) | 2022-12-26 |
| AU2020378438A1 (en) | 2022-06-02 |
| BR112022008908A2 (pt) | 2022-10-11 |
| CN115003335A (zh) | 2022-09-02 |
| EP4054545A4 (en) | 2024-02-14 |
| EP4054545A1 (en) | 2022-09-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2022005494A (es) | Sistemas de residencia gastrica para la administracion de agentes activos. | |
| WO2023141524A3 (en) | Dosage forms for gastric retention | |
| Butini et al. | Polypharmacology of dopamine receptor ligands | |
| EP4218735A3 (en) | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics | |
| AU2020379040A8 (en) | Gastric residence systems having a filament for improved gastric residence | |
| ZA201907746B (en) | 6-5 fused rings as c5a inhibitors | |
| IL272274B2 (en) | Antibodies 4h-7b Methods of using them | |
| MX2020006459A (es) | Compuestos de anillos fusionados 6,5 diaril sustituidos como inhibidores de c5ar. | |
| MX2022005592A (es) | Ligadores poliméricos para un sistema de residencia gástrica. | |
| EP4076593A4 (en) | SPRING LOADED MEDICAL NEEDLELESS INJECTION SYSTEM | |
| MX2019014292A (es) | Anillos 5-5 fusionados como inhibidores c5a. | |
| WO2015112776A3 (en) | Devices configured to provide treatment at an abreu brain thermal tunnel | |
| MX2019008921A (es) | Adenovirus recombinante de transgenes múltiples. | |
| MX2018015629A (es) | Sistema de vector viral adeno-asociado traslapado doble para la expresion de abc4a. | |
| MX2018008359A (es) | Sistemas y métodos para preparación de plaquetas. | |
| WO2008152115A3 (en) | Drug-releasing polyelectrolyte coating, method for forming a drug-releasing polyelectrolyte coating, and implantable device | |
| MX2018011799A (es) | Formas de dosificacion de liberacion prolongada disuasivas de abuso. | |
| MX2023001287A (es) | Bancos universales de células t específicas de antígeno y métodos de fabricación y uso terapéutico de los mismos. | |
| PH12018500432A1 (en) | Heteroaryl compounds and their use as therapeutic drugs | |
| AU2022299311A1 (en) | Therapeutic pressure, thermal, and/or other treatment modality systems and methods | |
| EP4385529A3 (en) | Devices for controlled delivery | |
| MX2018003380A (es) | Formulaciones de olanzapina de liberacion sostenida. | |
| PH12020500510A1 (en) | Prophylactic and/or therapeutic agent for diseases involving ido expression | |
| MX359757B (es) | Produccion de color caramelo bajo en 4-metilimidazol (4-mei) clase iv. | |
| MX2020006905A (es) | Composiciones farmaceuticas liquidas orales de aminosalicilatos. |